Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of endogenous GIP in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mechanisms in Endocrinology: FXR signalling - a novel target in metabolic diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effects of β-hydroxybutyrate on cognition in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Antidiabetic medication and risk of dementia in patients with type 2 diabetes. A nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Exendin(9-39)NH2 - recommendations for clinical use based on a systematic literature review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Mads R Andersen
  • Malte P Suppli
  • Jonatan I Bagger
  • Mikkel B Christensen
  • Gina L C Yosten
  • Filip K Knop
  • Asger Lund
View graph of relations

In 2008, the first evidence of a new hormone called neuronostatin was published. The hormone was discovered using a bioinformatic method and found to originate from the same preprohormone as somatostatin. This small peptide hormone of 13 amino acids and a C-terminal amidation was soon found to exert pleiotropic physiological effects. In animal studies, neuronostatin has been shown to reduce food intake and delay gastric emptying and gastrointestinal transit. Furthermore, neuronostatin has been shown to affect glucose metabolism by increasing glucagon secretion during situations when glucose concentrations are low. Additionally, neuronostatin has been shown to affect neural tissue and cardiomyocytes by suppressing cardiac contractility. The effects of neuronostatin have not yet been delineated in humans, but if the effects found in animal studies translate to humans it could position neuronostatin as a promising target in the treatment of obesity, hypertension and diabetes. In this review, we describe the discovery of neuronostatin and the current understanding of its physiological role and potential therapeutic applicability.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume185
Issue number4
Pages (from-to)R93-R101
ISSN0804-4643
DOIs
Publication statusPublished - 1 Sep 2021

    Research areas

  • Animals, Appetite Regulation/drug effects, Diabetes Mellitus/genetics, Gastric Emptying/drug effects, Humans, Hypertension/genetics, Muscle Contraction/drug effects, Myocytes, Cardiac/drug effects, Neurons/drug effects, Obesity/genetics, Peptide Hormones/pharmacology, Signal Transduction/drug effects, Somatostatin/chemistry

ID: 67568344